Psyence expands Australian clinical site network to five sites

Psyence Biomedical Ltd. (PBM) — Psyence Biomedical said it expanded its Australian clinical trial network from three to five sites, adding Ramsay Health Care and NeuroCentrix.

The sites support an ongoing Phase 2b trial run by Southern Star Research testing nature-derived psilocybin (NPX-5) for adjustment disorder in cancer patients in palliative care. The company said the added capacity should accelerate patient enrollment and broaden the study's geographic reach.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.